| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w13857 |
| 来源ID | Working Paper 13857 |
| The Impact of Medicare Part D on Pharmaceutical R&D | |
| Margaret E. Blume-Kohout; Neeraj Sood | |
| 发表日期 | 2008-03-12 |
| 出版年 | 2008 |
| 语种 | 英语 |
| 摘要 | Recent evidence suggests that Medicare Part D has increased prescription drug use among the elderly, and earlier studies have indicated that increasing market size induces pharmaceutical innovation. This paper assesses the impact of Medicare Part D on pharmaceutical research and development (R&D), using time-series data on (a) the number of drugs in clinical development by therapeutic class, and (b) R&D expenditures by firm. We demonstrate that the passage of Medicare Part D was associated with significantly higher pharmaceutical R&D for drug classes with higher Medicare market share, and for firms specializing in higher-Medicare-share drugs. |
| 主题 | Public Economics ; National Fiscal Issues ; Health, Education, and Welfare ; Health ; Development and Growth ; Innovation and R& ; D |
| URL | https://www.nber.org/papers/w13857 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/571531 |
| 推荐引用方式 GB/T 7714 | Margaret E. Blume-Kohout,Neeraj Sood. The Impact of Medicare Part D on Pharmaceutical R&D. 2008. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w13857.pdf（73KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
